title: Interleukin-1beta is a positive regulator of TIARP/STAMP2 gene and protein expression in adipocytes in vitro.
abstract: The impact of interleukin (IL)-1beta on tumor necrosis factor alpha-induced adipose-related protein (TIARP)/six-transmembrane protein of prostate 2 (STAMP2) was determined in adipocytes. TIARP/STAMP2 mRNA synthesis was significantly stimulated by IL-1beta in a dose- and time-dependent fashion in 3T3-L1 adipocytes. Signaling studies suggested that janus kinase 2, nuclear factor kappaB, and p44/42 mitogen-activated protein kinase are involved in IL-1beta-induced TIARP/STAMP2 mRNA expression. Furthermore, IL-1beta, TNFalpha, and IL-6 showed synergistic stimulatory effects on TIARP/STAMP2 gene expression. Moreover, both TIARP/STAMP2 mRNA synthesis and protein expression were induced by IL-1beta in fully differentiated human mesenchymal stem cell-derived adipocytes (hMSC-Ad). Taken together, TIARP/STAMP2 is highly upregulated in 3T3-L1 cells and hMSC-Ad by IL-1beta and might, therefore, modulate proinflammatory and insulin resistance-inducing effects of IL-1beta.
authors.affiliation: University of Leipzig, Department of Internal Medicine III, Leipzig, Germany.
authors.forename: Susan
authors.initials: S
authors.lastname: Kralisch
authors.forename: Grit
authors.initials: G
authors.lastname: Sommer
authors.forename: Sebastian
authors.initials: S
authors.lastname: Weise
authors.forename: Jana
authors.initials: J
authors.lastname: Lipfert
authors.forename: Ulrike
authors.initials: U
authors.lastname: Lossner
authors.forename: Manja
authors.initials: M
authors.lastname: Kamprad
authors.forename: Kathleen
authors.initials: K
authors.lastname: Schröck
authors.forename: Matthias
authors.initials: M
authors.lastname: Bluher
authors.forename: Michael
authors.initials: M
authors.lastname: Stumvoll
authors.forename: Mathias
authors.initials: M
authors.lastname: Fasshauer
mesh_terms: D041721:3T3-L1 Cells; D017667:Adipocytes / Q000166:cytology / Q000378:metabolism*; D000818:Animals; D002454:Cell Differentiation / Q000187:drug effects / Q000502:physiology; D004305:Dose-Response Relationship, Drug; D004357:Drug Synergism; D005786:Gene Expression Regulation / Q000187:drug effects* / Q000502:physiology; D006801:Humans; D007333:Insulin Resistance / Q000502:physiology; D053583:Interleukin-1beta / Q000819:agonists / Q000494:pharmacology*; D015850:Interleukin-6 / Q000819:agonists / Q000494:pharmacology; D053614:Janus Kinase 2 / Q000378:metabolism; D008565:Membrane Proteins / Q000096:biosynthesis*; D059630:Mesenchymal Stem Cells / Q000166:cytology / Q000378:metabolism; D051379:Mice; D019950:Mitogen-Activated Protein Kinase 1 / Q000378:metabolism; D016328:NF-kappa B / Q000378:metabolism; D010088:Oxidoreductases / Q000096:biosynthesis*; D012333:RNA, Messenger / Q000096:biosynthesis; D014409:Tumor Necrosis Factor-alpha / Q000819:agonists / Q000494:pharmacology
chemical_list: C508600:IL6 protein, human; D053583:Interleukin-1beta; D015850:Interleukin-6; D008565:Membrane Proteins; D016328:NF-kappa B; D012333:RNA, Messenger; C436323:Tiarp protein, mouse; D014409:Tumor Necrosis Factor-alpha; D010088:Oxidoreductases; C503310:STEAP4 protein, human; C507924:JAK2 protein, human; C507926:Jak2 protein, mouse; D053614:Janus Kinase 2; D019950:Mitogen-Activated Protein Kinase 1